Chemotherapy News and Research

Latest Chemotherapy News and Research

Synthetic cannabinoid could treat pain in diabetes patients

Oral synthetic cannabinoid nabilone may be effective for treating diabetic peripheral neuropathic pain, a study shows.

8 Nov 2012

Ethical issues in organ transplantation

The MacLean Center for Clinical Medical Ethics will focus its 24th Annual Dorothy J. MacLean Fellows Conference on ethical issues in organ transplantation and other broader ethical topics, including global health, pediatric immunization and end-of-life care.

8 Nov 2012

Carbohydrate-rich food intake may cause recurrence of colon cancer

Colon cancer survivors whose diet is heavy in complex sugars and carbohydrate-rich foods are far more likely to have a recurrence of the disease than are patients who eat a better balance of foods, a new study by Dana-Farber Cancer Institute researchers indicates.

8 Nov 2012

EpiCept, Immune Pharmaceuticals enter definitive merger agreement

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation today announced that they have entered into a definitive merger agreement. The transaction is anticipated to close during the first quarter of 2013 and is subject to satisfaction of certain customary closing conditions, including the approval of a majority of EpiCept shareholders.

8 Nov 2012

Synta announces interim results from docetaxel Phase 2b/3 trial on NSCLC

Synta Pharmaceuticals Corp. announced today that interim results from the Phase 2b/3 GALAXY trial will be presented at the Chemotherapy Foundation Symposium in New York City on Friday, November 9 during the 11:45 a.m. session on new agents for lung cancer. Presenting this data at the conference will be Dr. Suresh Ramalingham, Professor, Hematology & Medical Oncology, and Director, Translational Thoracic Malignancies Program, of the Winship Cancer Institute of Emory University.

7 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

MASP-1 enzyme plays a central role in activating the complement system

Researchers from Aarhus University, Denmark, have now discovered an important mechanism behind one of our most fundamental lines of immune function. The discovery has been published in the esteemed scientific journal, The Journal of Immunology, where it has been highlighted as a top story.

7 Nov 2012

FDA grants Priority Review to ImmunoGen’s trastuzumab emtansine BLA

ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Genentech, a member of the Roche Group, has disclosed that the U.S. Food and Drug Administration (FDA) has officially accepted the Biologics License Application (BLA) for trastuzumab emtansine and granted it Priority Review.

7 Nov 2012

Viewpoints: Fight for the Senate will impact GOP effort to void health law; Figuring out insurance is tough even for health economist

For Republicans intent on unraveling President Obama's accomplishments, electing Mitt Romney has been only one part of the equation. Almost as important was installing a Republican majority in the United States Senate, where 50 votes (plus the vice president) would be necessary to repeal much of health care reform, roll back tax increases on the rich and gut social welfare programs. The party's hopes, however, have been severely damaged in recent weeks.

6 Nov 2012

PsiOxus receives UK government grant to initiate ColoAd1 Phase I/II trial for ovarian cancer

PsiOxus Therapeutics, Ltd., a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.

5 Nov 2012

Vitamin D deficiency: an interview with Kellie Bilinski

We know that vitamin D is important in keeping bones strong. In the last 30-40 years it has also been realized that vitamin D has a lot of other roles in the body. Vitamin D essentially has a role in any cell in the body that has a vitamin D receptor.

5 Nov 2012

New insight on ability of certain PAH-derived lesions to evade DNA repair machinery

A person doesn't have to go far to find a polycyclic aromatic hydrocarbon (PAH). These carcinogen precursors are inhaled through automobiles exhaust during the morning commute, are present in a drag of cigarette smoke, and are part of any barbequed meal.

4 Nov 2012

Research roundup: Lowering health costs of the poorest sick; Local variations in health spending

Olmstead County, Minn., which earlier required just restaurants to be smoke-free, enacted a law in 2007 that banned smoking in all workplaces. Researchers reported "a substantial decline in the incidence of MI from 18 months before the smoke-free restaurant law was implemented to 18 months after the comprehensive smoke-free workplace law was implemented 5 years later.

3 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Adding angiogenesis inhibitor to anti-HER2 drugs extends survival in mice with breast cancer

Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. In their report published online in PNAS Plus, Massachusetts General Hospital (MGH) investigators report the first preclinical study combining antiangiogenic and anti-HER2 drugs in an animal model of brain metastatic breast cancer.

3 Nov 2012

Scientists identify biomarker associated with tamoxifen resistance in women with breast cancer

Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.

From The University of Manchester 3 Nov 2012

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Physician-researchers at Indiana University School of Medicine have reported the first effective therapy for a class of previously untreatable and potentially life-threatening tumors often found in children.

2 Nov 2012

Link between ChemoFx Drug Response Marker results and RFS of cervical cancer patients

A new study reporting an association between ChemoFx Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.

2 Nov 2012

Repeated surgeries may improve survival for patients with glioblastomas

People who undergo repeated surgeries to remove glioblastomas - the most aggressive and deadliest type of brain tumors - may survive longer than those who have just a one-time operation, new Johns Hopkins research suggests.

2 Nov 2012

Malarial drug shows promise in stopping breast cancer

A malarial drug is showing promise in stopping breast cancer before it starts, Mason researchers are discovering during a clinical trial.

2 Nov 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

Synthetic cannabinoid could treat pain in diabetes patients

Ethical issues in organ transplantation

Carbohydrate-rich food intake may cause recurrence of colon cancer

EpiCept, Immune Pharmaceuticals enter definitive merger agreement

Synta announces interim results from docetaxel Phase 2b/3 trial on NSCLC

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

MASP-1 enzyme plays a central role in activating the complement system

FDA grants Priority Review to ImmunoGen’s trastuzumab emtansine BLA

Viewpoints: Fight for the Senate will impact GOP effort to void health law; Figuring out insurance is tough even for health economist

PsiOxus receives UK government grant to initiate ColoAd1 Phase I/II trial for ovarian cancer

Vitamin D deficiency: an interview with Kellie Bilinski

New insight on ability of certain PAH-derived lesions to evade DNA repair machinery

Research roundup: Lowering health costs of the poorest sick; Local variations in health spending

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Adding angiogenesis inhibitor to anti-HER2 drugs extends survival in mice with breast cancer

Scientists identify biomarker associated with tamoxifen resistance in women with breast cancer

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Link between ChemoFx Drug Response Marker results and RFS of cervical cancer patients

Repeated surgeries may improve survival for patients with glioblastomas

Malarial drug shows promise in stopping breast cancer

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in